Work

Diagnostic accuracy of a salivary polyamine-based cancer risk assessment test: an exploratory case-control study

Year: 2026
Type: article
Study design: Observational Study
Abstract: Background SalivaChecker® assesses cancer risk based on salivary polyamine profiles. However, its ability to distinguish patients with established cancer from individuals without clinically significant abnormalities remains insufficiently characterized. This study evaluated the exploratory discrimination of SalivaChecker® in a selected exploratory case-control sample.Methods This exploratory case-control diagnostic-accuracy study included patients with established lung, pancreatic, gastric, colorectal, breast, or oral cancer who underwent perioperative oral management and apparently healthy individuals attending comprehensive health checkups. Saliva samples were collected under standardized morning fasting conditions and analyzed using SalivaChecker®. A positive result was defined as a high or very high risk classification for at least one of the six cancer types. Sensitivity and apparent specificity were estimated within the study sample.Results Among 101 participants, including 66 patients with cancer and 35 apparently healthy controls, SalivaChecker® was positive in 45 patients with cancer and 8 controls. The test-positive rate was higher in patients with cancer than in controls (45/66 [68.2%] vs 8/35 [22.9%]; unadjusted OR, 7.23; 95% CI, 2.81–18.58; Fisher’s exact test, p = 0.0000199). Clinically established cancer status remained associated with test positivity after adjustment for age and sex (adjusted OR, 4.861; 95% CI, 1.581–14.950; p = 0.006).Conclusion In this selected case-control sample, SalivaChecker® showed a moderate ability to distinguish patients with established cancer from apparently healthy controls. Because of the case-control design, spectrum bias, and differences in age between the groups, these estimates should not be extrapolated to asymptomatic screening populations or routine dental practice. Prospective studies in the intended-use population are required to determine screening performance and clinical utility.
Language: English
Open Access status: gold
Estimated APC paid: $1,165
OpenAlex ID: W7236395660
FWCI:
Cites: 18
Cited by:
Related to: 10